Fulcrum Therapeutics
As of the edition of 20 October 2026, Fulcrum Therapeutics runs 2 drugs; it is on route A at 2 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Stopped | 2 |
| Total | 2 |
Where it needs a new molecule
Route A at 2 targets, route B at 0 targets.
All 2 rows on route A or B
In the product2 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 2 targets where Fulcrum Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Inherited and neonatal: 8 trials led
- Blood and lymph: 4 trials led
- Bones, joints and muscles: 4 trials led